Favipiravir
- COVID-19
Lupin Launched Favipiravir as Covihalt for COVID 19 Treatment
Lupin's Covihalt dosage strength has been developed keeping in mind the convenience of administration. It is available as 200 mg…
Read More » - COVID-19
Price War in Favipiravir Space to Combat COVID-19
Initially, it was Glenmark Pharma which launched the drug for Rs 103 per tablet in June, it revised the price…
Read More » - COVID-19
Cost Effective Process Technology of Favipiravir Developed by CSIR Used by M/s Cipla Ltd.
CSIR constituent lab CSIR-Indian Institute of Chemical Technology (CSIR-IICT) has developed a cost effective process using locally available chemicalsto synthesize.
Read More » - News
Glenmark Announces Results of Phase 3 Clinical Trial of Favipiravir on COVID Patients
The open-label randomized, multicenter clinical trial, conducted in 150 patients, evaluated the efficacy and safety of Favipiravir plus standard supportive…
Read More » - LimeLight
Biophore Claims the Validation for Scaled Up Production of Made-In-India Favipiravir for Covid-19
Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well.…
Read More » - News
Glenmark’s Favipiravir is Different from Livealth Bio Pharma’s Livfavir
The false news says, “Fabiflu 200 mg has been priced at Rs 103 per tablet by Glenmark. After an inquest,…
Read More » - Sectors
COVID-19 Drug By Glenmark Set for Market at Rs 103 Per Tablet After Getting DCGI Approval
The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for…
Read More »